Skip to content

Follow-up of patients with idiopathic ventricular fibrillation, the FU-IVF study.

Follow-up of patients with idiopathic ventricular fibrillation, the FU-IVF study. - FU-IVF study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40680
Enrollment
95
Registered
2014-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

life-threatening heart rythm disorder ventricular fibrillation

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All documented patients who had an OHCA, who were successfully resuscitated and had ventricular fibrillation as initial rhythm and were finally diagnosed as idiopathic VF.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
Alternative diagnoses discovered during follow-up in patients with IVF.

Secondary

MeasureTime frame
• Description of the population of our cohort (Prognosis, recurrence of arrhythmias, therapy, (in)appropriate shocks, presence of cardiac anomalies not sufficient for an alternative diagnosis) • The detection of prognostic factors for IVF (family history, use of medication, gender, ECG features etc). • Discovering new susceptibility genes for idiopathic VF In patients who have no structural or electrical heart disease nor a known gene mutation responsible for ventricular fibrillation, we will pursue a *hypothesis- driven* approach and search for mutations in genes that are predicted to be of importance in IVF, based on existing gene networks and existing literature. When no susceptibility genes are discovered, sequencing will be extended to whole exome sequencing. • Quality of life measurements of IVF patients, compared to the healthy population.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)